Avalo Therapeutics, Inc. filings document clinical, financial, capital-structure, and governance disclosures for a biotechnology issuer developing IL-1β-based therapies. Recent 8-K reports cover abdakibart LOTUS trial materials in hidradenitis suppurativa, operating and financial results, investor presentation updates, and material agreements related to milestone obligations from the AlmataBio acquisition.
The company's proxy materials describe shareholder voting matters, board composition, executive compensation, equity awards, and governance practices. Avalo's filing record also includes disclosure categories tied to common stock and pre-funded warrant financing, Nasdaq inducement awards, risk and operating updates, and formal reporting of material events affecting its clinical-stage business.
Insider Trading Alert: Michael Thomas Heffernan, Director of Avalo Therapeutics (AVTX), was granted stock options on June 17, 2025. The transaction details include:
- Received 29,500 stock options to purchase common stock
- Exercise price set at $4.47 per share
- Options will vest 100% on June 17, 2026 (first anniversary of grant date)
- Options expire on June 17, 2035
- Vesting is contingent on continued service as Director
This Form 4 filing represents a standard director compensation grant and was reported within the required two-business-day filing window. The transaction was executed directly (not through indirect ownership) and was documented via power of attorney by Donald R. Reynolds.
Director Rita Jain of Avalo Therapeutics (AVTX) received a stock option grant on June 17, 2025, according to a Form 4 filing. The key details include:
- Granted 40,200 stock options to purchase common stock at an exercise price of $4.47 per share
- Options will vest in three equal installments on the first, second, and third anniversary of the grant date
- Options expire on June 17, 2035
- Vesting is contingent on continued service as director
This equity compensation grant appears to be part of the company's director compensation program. The filing was signed by Donald R. Reynolds via power of attorney on June 18, 2025. This transaction represents a new position for the director, as no prior holdings were reported.